Clinical Trials Logo

Burkitt's Lymphoma clinical trials

View clinical trials related to Burkitt's Lymphoma.

Filter by:

NCT ID: NCT00807495 Completed - Clinical trials for Mantle Cell Lymphoma

Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

Start date: February 10, 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the anti-tumor activity of alisertib (MLN8237) in participants with relapsed or refractory non-hodgkin's lymphoma.

NCT ID: NCT00669877 Completed - Burkitt's Lymphoma Clinical Trials

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

Start date: August 2002
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if intensive chemotherapy given over 6 months can help to control or cure Burkitt's leukemia, Burkitt's lymphoma, or small non-cleaved cell B-cell leukemia or lymphoma. Another goal is to see how well this treatment works when given with Rituximab. The safety of the combined treatment will also be studied.

NCT ID: NCT00412243 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients

Start date: March 2006
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of the drugs clofarabine and cyclophosphamide that can be given together in the treatment of relapsed or refractory ALL. The safety of the combination treatment will also be studied. Objectives: Phase I: 1. To establish toxicities and safety of the proposed combination 2. To establish the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of the combination to proceed with the phase II part of the study Phase II: 3. To establish the efficacy (complete and overall response) of the proposed combination. 4. To analyze pharmacokinetic (PK) and pharmacodynamic (PD) properties of clofarabine as well as the impact on DNA repair of leukemic blasts with the proposed combination.

NCT ID: NCT00388193 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Rituximab Combined With Chemotherapy in Burkitt`s Lymphoma

Start date: August 2006
Phase: Phase 2
Study type: Interventional

The purpose of this clinical trial is to prove the efficacy of the following new regimen treatment: - Administration of anti-CD20 (Rituximab) combined with chemotherapy. - Combined treatment with high doses of methotrexate and high doses of cytarabine with conventional cytostatics (block C) - Prophylactic administration of G-CSF after all chemotherapy cycles - local irradiation after 6 cycle if CNS was affected or if there are residual tumour

NCT ID: NCT00199082 Completed - Clinical trials for Lymphoblastic Lymphoma

Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults

Start date: July 2002
Phase: Phase 4
Study type: Interventional

The study evaluates the efficacy and tolerability of alternating short cycles of high-dose and conventional chemotherapy in combination with rituximab in CD20 positive patients, followed by local radiation therapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. A dose-reduced regimen is offered for patients estimated to be over 55 years, biologically.